<DOC>
	<DOC>NCT02940314</DOC>
	<brief_summary>The purpose of this study is to compare the safety and pharmacokinetic characteristics after administration of HIP1503 and HGP1103 in healthy male volunteers.</brief_summary>
	<brief_title>Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>1. Healthy male volunteers, age 19 to 45 years. 2. The result of Body Mass Index(BMI) 17.5 kg/m2~ 30.5 kg/m2, body weight over 55kg. 3. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing. 1. Presence of medical history or a concurrent disease, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system. 2. Medical history of Gastrointestinal Diseases that effects drug absorption (esophageal disease, chronic disease) or surgery( except appendectomy , herniolaparotomy) 3. sit SBP &gt; 140 mmHg, sit DBP &gt; 90 mmHg 4. Alcohol or Drug abuse within 1 year</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>